An Open Study of Atomoxetine (LY139603) in Adult Subjects With Attention-Deficit/Hyperactivity Disorder
Phase of Trial: Phase II
Latest Information Update: 03 Nov 2010
At a glance
- Drugs Atomoxetine (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Adverse reactions
- Sponsors Eli Lilly
- 31 Aug 2018 Biomarkers information updated
- 25 Dec 2009 Actual patient number (45) added as reported by ClinicalTrials.gov.
- 30 Oct 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.